Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | TLR2 | O60603 | 3/20 | 0.46 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28629484 | 1.00 | KMT2A (0.58) | KMT2ATLR2TLR1MDM2MAPT | |
| SCHEMBL28629485 | 1.00 | KMT2A (0.58) | KMT2ATLR2TLR1MDM2MAPT | |
| Hydrochloric Acid SCHEMBL29380070 | 0.99 | KMT2A (0.57) | KMT2ATLR2TLR1MDM2MAPT | |
| SCHEMBL4906458 | 0.92 | KMT2A (0.54) | KMT2ATLR2TLR1MDM2MAPT | |
| Hydrochloric Acid SCHEMBL29902249 | 0.92 | KMT2A (0.52) | KMT2ATLR2TLR1MDM2EPHX2 | |
| SCHEMBL30887302 | 0.89 | KMT2A (0.63) | KMT2ATLR2EPHX2DPP8DPP7 | |
| SCHEMBL14682729 | 0.89 | KMT2A (0.63) | KMT2ATLR2EPHX2DPP8DPP7 | |
| SCHEMBL15160784 | 0.89 | KMT2A (0.63) | KMT2ATLR2EPHX2DPP8DPP7 | |
| SCHEMBL12972620 | 0.89 | KMT2A (0.63) | KMT2ATLR2EPHX2DPP8DPP7 | |
| SCHEMBL6669959 | 0.89 | KMT2A (0.53) | KMT2ATLR2TLR1MDM2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | TRUSTEES OF TUFTS COLLEGE | 2026-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | FIBP, FRS2, FGFR1 | KMT2A 3715/4885TLR2 4438/4885TLR1 4520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.